Gossamer Bio, Inc. (GOSS): Total Liabilities
$295.01M
As of 2025-12-31
$170.90M
As of 2026-06-30
+4.3%
3-year compound annual growth
+6.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $295.01M | +3.2% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $285.80M | +14.7% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $249.15M | -4.3% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $260.37M | +17.2% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $222.19M | +1.6% | 2023-03-17, Balance as of period end |
| 2020-12-31 | $218.75M | +195.1% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $74.12M | +250.9% | 2021-02-26, Balance as of period end |
| 2018-12-31 | $21.12M | n/a | 2020-03-24, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $295.01M | +3.2% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $77.45M | -49.2% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $53.48M | -23.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $214.26M | +486.9% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $153.75M | +7.8% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $194.09M | +20.1% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $52.28M | -1.4% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $7.67M | +67.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $119.41M | +123.3% |
Compare GOSS, LXRX, PTGX, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗